STROKE TREATMENT WHAT IS A STROKE? When the blood supply to the brain is disturbed in some way and brain cells are starved of oxygen causing some cells to die and leaving other cells damaged or dead it's call a STROKE. Most strokes happen when a blood clot blocks one of the arteries (blood vessels) that carries blood to the brain. Brain cells are starved of oxygen causing some cells to die and leaving other cells damaged when the blood supply to the brain was disturbed in some way. This type of stroke is called an ischemic stroke. STROKE- Transient ischemic attack (TIA) is a short-term stroke that lasts for less than 24 hours. The oxygen supply to the brain is restored quickly, and symptoms of the stroke disappear completely. A transient stroke needs prompt medical attention as it is a warning of serious risk of a major stroke. What are the effects of a stroke? People can be affected in quite different ways. This partly depends on which area of the brain is damaged from STROKE, because different parts control different abilities such as speaking, memory, swallowing and moving. The most common signs of a stroke are weakness, paralysis … Continue reading →

Northwestern University provides a strong foundation in core genetic counseling skills and identifies each students strengths in order to ignite the passion and lifelong commitment to learning that is critical to professional development. Graduates not only feel extremely capable in multiple clinical settings and specialties, but also recognize how valuable their training has been in preparing them for expanded genetic counseling careers. Since the inception of the Northwestern University Graduate Program in Genetic Counseling in 1990, the leaders of the program have strived to look to the future of the genetic counseling profession to help guide the overall administration and curriculum. The field of genetics has evolved rapidly over time, and graduate programs need to be aware of the changes that will continue to shape and influence the profession. Northwestern has continued to successfully evolve to meet these changing needs. There are several strengths that allow Northwestern to maintain this cutting edge: This unique combination, along with the personalized attention a student receives during their training, creates an exciting learning environment and is one of the major strengths of the Northwestern program. We believe our students deserve a strong science, research and psychosocial curriculum. In addition, Northwestern is proud to … Continue reading →

Successful treatment of spinocerebellar ataxia 6 by systems therapy with medicinal herbs. T. Okabe Dept Integrated Traditional Medicine, University of Tokoy Graduate School of Medicine, Hongo, Tokyo, Japan. The spinocerebellar ataxias (SCAs) are clinically and genetically a heterogeneous group of neurodegenerative disorders. At present,we have no effective therapeutic tools. We report here two cases of spinocerebellar ataxia 6(SCA6)with typical symptoms, which were improved after administration of a mixture of traditional medicinal herbs. A 60-year-old Japanese female suffered from gait disturbance, ataxia and dizziness. Head MRI revealed a typical atrophic image in cerebellum. Genetic tests revealed an expanded allele of 22 CAG repeats at the spinocerebellar ataxia type 6 locus. She was diagnosed as SCA6. A mixture of 18 medicinal herbs (modified Chinkan-sokufu-to) was given according to the differential diagnosis based on the guideline of traditional herbal medicine. Most of the symptoms were remarkably improved after 60 days of the herbal treatment. One year after discontinuation of the treatment, she complained of gait ataxia. She was treated with the modified Chinkan-sokufu-to for 60 days. Gait ataxia was markedly improved by the second treatment. 15 months after discontinuation of the second treatment, she complained of gait ataxia again. The same remedy was … Continue reading →

CLINAM 9 / 2016 Conference and Exhibition European & Global Summit for Cutting-Edge Medicine June 26 29, 2016 Clinical Nanomedicine and Targeted Medicine - Enabling Technologies for Personalized Medicine Scientific Committee: Chairman Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH). MEMBERS Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL). Dr. med. h.c. Beat Ler, MA, European Foundation for Clinical Nanomedicine, Basel (CH) Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (UK). Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D) Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (DE) Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zrich (CH). Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense (DK). Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital; Founder of BIND Therapeutics, Biosciences and Blend Therapeutics, Cambridge, Boston (USA) Prof. Dr. Dong Soo Lee, M.D. Ph. Chairman Department of Nuclear Medicine Seoul National University Seoul, Korea (invited) Prof. Dr.Lajos Balogh, Editorin in Chief, Nanomedicine, Nanotechnologyin, Biology and Medicine, Elsevier&nbsp and Member&nbsp of theExecutive Board, … Continue reading →

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hrgdr7/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 296 of these are profiled in part II of the report along with tabulation of 280 alliances. Of these companies, 167 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 62 Tables and 17 Figures. The bibliography contains 1,200 selected references, which are cited in the text. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic … Continue reading →